{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:11:16Z","timestamp":1791472276098,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.lungcan.2023.107184","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T02:35:12Z","timestamp":1680230112000},"page":"107184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer \u2013 A multicenter observational analysis"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-7129","authenticated-orcid":false,"given":"Nikolaj","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten Gerriet","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Misch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylke","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"L\u00fcders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Raspe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Hilbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Senger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik P.","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lungcan.2023.107184_b0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107184_b0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107184_b0015","first-page":"1","article-title":"Immunotherapy for advanced non-small cell lung cancer: A decade of progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"9","key":"10.1016\/j.lungcan.2023.107184_b0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107184_b0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107184_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.746853","article-title":"Biological bases of immune-related adverse events and potential crosslinks with immunogenic effects of radiation","volume":"12","author":"Bardoscia","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107184_b0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107184_b0040","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2023.107184_b0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107184_b0050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107184_b0055","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2021.05.017","article-title":"Imaging features of pulmonary immune-related adverse events","volume":"16","author":"Pozzessere","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2023.107184_b0060","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107184_b0065","doi-asserted-by":"crossref","unstructured":"J. Haanen, F. Carbonnel, C. Robert, et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl 4) (2018) iv264-iv266.","DOI":"10.1093\/annonc\/mdy162"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107184_b0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: Management of immunotherapy-related toxicities, Version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107184_b0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2023.107184_b0080","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1148\/rg.2015140334","article-title":"American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in knowledge since 2002","volume":"35","author":"Sverzellati","year":"2015","journal-title":"Radiographics"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107184_b0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107184_b0090","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS\/JRS\/ALAT Clinical Practice Guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107184_b0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107184_b0100","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107184_b0105","doi-asserted-by":"crossref","unstructured":"K.R. Voong, S.Z. Hazell, W. Fu, et al., Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer, 20(4) (2019) p. e470-e479.","DOI":"10.1016\/j.cllc.2019.02.018"},{"key":"10.1016\/j.lungcan.2023.107184_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.570233","article-title":"Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy","volume":"10","author":"Barron","year":"2020","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107184_b0115","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1002\/cam4.1579","article-title":"Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study","volume":"7","author":"Cui","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2023.107184_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107184_b0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2023.107184_b0130","article-title":"Toxicity profile of combining PD-1\/PD-L1 inhibitors and thoracic radiotherapy in non-small cell lung cancer: A systematic review","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107184_b0135","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1183\/09031936.00148613","article-title":"Nonspecific interstitial pneumonia: survival is influenced by the underlying cause","volume":"45","author":"Nunes","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107184_b0140","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1002\/cam4.2974","article-title":"Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy","volume":"9","author":"Watanabe","year":"2020","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107184_b0145","doi-asserted-by":"crossref","first-page":"p. FSO378","DOI":"10.2144\/fsoa-2018-0123","article-title":"Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review","volume":"5","author":"McGovern","year":"2019","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.lungcan.2023.107184_b0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2021.01.001","article-title":"Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer","volume":"157","author":"Cousin","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107184_b0155","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00165-2019","article-title":"Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study","volume":"6","author":"Pozzessere","year":"2020","journal-title":"ERJ Open Res."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107184_b0160","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107184_b0165","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02442-2018","article-title":"Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy","volume":"54","author":"Bauer","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2023.107184_b0170","doi-asserted-by":"crossref","unstructured":"M.M. Leeflang, Y.J. Debets-Ossenkopp, J. Wang, et al., Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst. Rev., (12) (2015) CD007394.","DOI":"10.1002\/14651858.CD007394.pub2"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107184_b0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cmi.2021.08.017","article-title":"Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"28","author":"Senecal","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107184_b0180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade >\/=2 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107184_b0185","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107184_b0190","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.107184_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2023.107184_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: A systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107184_b0205","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12561-016-9157-9","article-title":"Understanding landmarking and its relation with time-dependent Cox regression","volume":"9","author":"Putter","year":"2017","journal-title":"Stat. Biosci."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:08Z","timestamp":1759237508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"alternative-id":["S0169500223001228"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107184","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer \u2013 A multicenter observational analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107184"}}